CytoScan XON Suite
Unravel the exome odyssey
Overcome the challenges of the exome odyssey with reliable single-exon deletion and duplication detection using the Applied Biosystems CytoScan XON Suite, which includes arrays, reagents, and easy-to-use software for cost-effective and streamlined analysis of exon-level CNVs. Designed to cover the whole genome, with increased coverage in 7,000 clinically relevant genes, the CytoScan XON Suite provides CNV data that works as a strong complement to mutation analysis performed by next-generation sequencing (NGS).
Our specialists are eager to meet with you, assess your needs, and review example data. Please click the box below to request a consultation with a specialist.
With the CytoScan XON Suite, you can:
- Comprehensively detect single-exon deletions and duplications in a cost-effective manner
- Complement NGS mutation analysis with reliable exon-level deletion and duplication detection
- Confirm CNV findings from alternative technologies
- Simplify and streamline sequence variant analysis
Our partners are making significant positive strides in reproductive health. Watch the video below to learn more about single-exon deletion and duplication detection with CytoScan XON Suite at the Greenwood Genetic Center in Greenwood, South Carolina.
Copy number variations (CNVs) are well-recognized genomic structural variants associated with genetic disorders. Chromosomal microarray analysis (CMA) successfully detects submicroscopic CNVs, and since 2010, is used as a first-tier test for the detection of CNVs related to intellectual disability, developmental delay, autism spectrum disorders, and congenital abnormalities .
In addition to the CNVs involving whole-genomic regions as routinely detected by CMA, several clinical research studies have investigated CNVs involving single or multiple exonic deletions and duplications, and identified correlation to neurodevelopmental delay , blindness , and deafness , among others. Additionally, intragenic CNVs are more prevalent than previously suspected in Mendelian disorders, and should be considered when analyzing these samples in a clinical research setting . Today, we know that up to 40% of intragenic mutations can involve only one or two exons, so it is imperative for genomic technologies to maximize coverage within a gene .
With the advent of NGS in particular, the increasing use of whole-exome sequencing to assess single-nucleotide variants (SNVs) has shown successful detection of small indels, and methods to call copy number changes from NGS data have emerged. As adoption and data analysis of whole-exome sequencing evolves in the clinical research setting, it is critical to detect both haplo-insufficient mutation aberrations as well as aberrations in genes associated with recessive disorders for which a mutation is identified in only one allele. Thus, current NGS tools exhibit significant false-positive rates and calls must be verified using orthogonal methodologies .
The CytoScan XON Suite is an exon-level copy number assay providing the sensitivity and flexibility required to improve and complement the analysis of these significant variants for clinical research.
Biallelic deletions of the Waardenburg II syndrome gene, SOX10, cause a recognizable arthrogryposis syndrome
Learn more about how Stevenson et al. used CytoScan XON Suite to analyze biallelic deletions in SOX10, a gene associated with Waardenburg syndromes type II and IV.
- Whole-exome sequencing showed no variants in PAX3, SOX10, MITF, EDN3, EDNRB and SNA12
- Two deletions in SOX10 found by genomic array and quantitative PCR
- Microarray analysis performed using CytoScan XON assay (6.85 million probes on platform with emphasis on exonic coverage of the RefSeq genes)
Sensitive exon-level copy number and superior coverage across the whole genome
Current NGS gene panels vary widely from a handful of genes to a few thousand. Comprehensive and effective detection of deletions and duplications to match these panels can be challenging from a cost and lab efficiency perspective when using multiplex ligation-dependent probe amplification (MLPA™) assays or exome arrays for medical research. Additionally, custom-made deletion and duplication arrays lack the flexibility to include any new gene of interest that is relevant to a particular disease and creates increased burden for verification and analytical validation of the new content.
The CytoScan XON Suite is a microarray solution which detects single-exon deletion and duplication events with high sensitivity in key relevant genes in addition to providing whole-genome coverage (Figure 1). The single-nucleotide polymorphism (SNP) probes allow sample tracking, duotrio, and loss of heterozygosity (LOH) analysis.
Smart design improves resolution in key genes
The CytoScan XON Suite content was designed through empirical selection from a pool of over 49 million probes for copy number responses across the genome. The best performing probes were selected to cover key relevant genes and the exons within them. Any gaps were filled with additional probes flanking 500 bp from the targeted region, ensuring each exon contains enough probes to make a reliable call (Figure 2).
Reporting flexibility with gene panel or gene-level tier analysis
The flexibility of Chromosome Analysis Suite (ChAS) data analysis software enables easy viewing and summarizes the exon-level CNV results in various ways based on your specific clinical research needs.
Gene panel analysis
Simplify result reporting by utilizing your preferred gene list or panel in the intuitive ChAS software. This analysis feature allows you to obtain exon-level CNV results limited to the gene panel you upload and view only the genes of interest with restriction mode enabled (Figure 3).
Gene-level tier analysis
Gene-level tier analysis is incorporated into the user-friendly ChAS software, providing a novel and flexible approach, where the software displays results by gene-level tiers based on clinical research relevance. This unique functionality allows visualization of CNVs for a targeted number of clinically relevant genes (Level 1), or expands the gene-level tiers for a whole-genome view (Table 1). Thus, the user determines the gene-level tiers of interest for analysis and reporting.
|Level||Number of genes||Description|
|1||7,003||Includes genes with the strongest relevance to clinical research; for example, genes related to intellectual disability, developmental delay, autism spectrum disorder, congenital anomalies, epilepsy, primary immunodeficiencies, hereditary cancer, as well as cardiac, metabolic, neuromuscular, eye, and hearing disorders, among others|
|2||3,813||Includes ClinVar genes not covered in Level 1|
|3||5,817||Includes OMIM® genes not covered in Levels 1 and 2|
|4||9,347||Includes RefSeq genes not covered in Levels 1, 2, and 3|
Table 1. Description of gene-level tiers.
ChAS software workflow
6.85 million empirically selected probes for whole-genome coverage including:
|Sensitivity||95% sensitivity for the detection of exon-level CNVs*|
Total number of genes with coverage: 25,980
* Sensitivity calculated from gene-level tier 1.
Please visit our CytoScan XON Suite Resource Library to access the latest webinars, posters, and literature.
1. Miller DT, Adam MP, Aradhya S et al. (2010) Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 86:749-764.
2. Zahir F et al. (2016) Intragenic CNVS for epigenetic regulatory genes in intellectual disability: survey identifies pathogenic and benign single exon changes. Am J Med Genet Part A 170A:2916-2926.
3. Neuhaus C, Eisenberger T et al. (2017) Next-generation sequencing reveals the mutational landscape of clinically diagnosed Usher syndrome: copy number variations, phenocopies, a predominant target for translational read-through, and PEX26 mutated in Heimler syndrome. Mon Genet Genomics 5:531-552.
4. Ji H et al. (2014) Combined examination of sequence and copy number variations in human deafness genes improves diagnosis for cases of genetic deafness. BMC Ear Nose Throat Disord 14:
5. Aradhya S, Lewis R, Tahrra B et al. (2012) Exon-level array CGH in a large clinical cohort demonstrates increased sensitivity of diagnostic testing for Mendelian disorders. Genet Med 14:594-603.
6. Retterer K, Scuffins J et al. (2015) Assessing copy number from exome sequencing and exome array CGH based on CNV spectrum in a large clinical cohort. Genet Med 17:623-629.
7. Mason-Suares H, Landry L, Lebo M (2016) Detecting copy number variation via next generation technology. Curr Genet Med Rep 4:74-85.